NCT05131373View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

November 27, 2023

Study Completion Date

November 27, 2023

Conditions
Acne VulgarisAcne
Interventions
DRUG

ORG101 - Experimental 1

C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals

DRUG

ORG101PL - Placebo 1

Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals

Trial Locations (6)

23538

UKSH, Campus Lübeck, Lübeck

42287

CentroDerm, Wuppertal

44791

Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB), Bochum

48455

Fachklinik Bad Bentheim, Bad Bentheim

60590

Universitätsklinikum Frankfurt, Frankfurt am Main

72074

Universitäts-Hautklinik Tübingen, Tübingen

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter